Filing Flows › Health Care › Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics (GLUE) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Monte Rosa Therapeutics (GLUE) Q3 2026 earnings results →
Q3 2026 Revenue up 326% year over year to $54.4M · 6¢ of every $1 of revenue kept as net profit · operating margin -3.6%
Monte Rosa Therapeutics made $54.4M in Q3 2026 (+326% Y/Y). Operating margin -3.6%, net earnings $3.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $54.4M in Q3 2026, up 326% year over year and up 506% from the previous quarter.
Operating costs exceeded revenue by $1.9M, an operating margin of -3.6%. Total costs grew 23% against revenue growth of 326%. The fastest-growing cost line was Research & development (+24%). Net earnings were $3.1M. The effective tax rate was 18.9%. Non-operating items added $5.7M, 151% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$41.0M. Non-cash charges added back $2.9M of depreciation and amortization and $6.3M of share-based compensation. Working capital and other items used $53.2M. Capital expenditures of $1.6M exceeded it, leaving free cash flow of −$42.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $54.4M | +326% | -3.6% | $3.1M | −$41.0M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $9.0M | -61% | -547.8% | −$43.4M | −$44.1M |
| Q1 2026 | 10-Q | May 7, 2026 | $4.2M | -95% | n/m | −$44.5M | −$37.4M |
| Q4 2025 | 10-K | Mar 17, 2026 | $2.8M | -95% | n/m | −$46.1M | −$43.0M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $12.8M | +38% | -258.3% | −$27.1M | $100M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $23.2M | +394% | -67.1% | −$12.3M | −$34.7M |
| Q1 2025 | 10-Q | May 8, 2025 | $84.9M | 80× | 51.9% | $46.9M | −$45.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic.
In its own words, from its 8-K, filed Aug 6, 2026.
Monte Rosa Therapeutics against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +326% against the peers' median +29%. Operating margin: -3.6% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics | Q3 2026 | $54.4M | +326% | -3.6% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Monte Rosa Therapeutics 10-Q on SEC EDGAR · CIK 1826457 · Biological Products, (No Diagnostic Substances)
13F: who owns GLUE and who is buying
More on GLUE
- How Monte Rosa Therapeutics makes money: revenue by segment
- Monte Rosa Therapeutics next earnings date and what analysts expect
- Monte Rosa Therapeutics stock forecast, price target and fair value
- Who owns Monte Rosa Therapeutics stock: holders, funds and Congress trades
- Monte Rosa Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results